Repertoire Sequencing Survey Request Form 2019-02-21T08:54:15+00:00

SURVEY RESULTS: EUROPEAN IMMUNOTHERAPY COMPANIES HAVE GREAT CONCERNS REGARDING INCREASING COST AND LONG DEVELOPMENT TIMELINES
The Promise of Adopting Repertoire Sequencing in Drug Discovery and Development of Immunotherapies

POTENTIAL VALUE OF REPERTOIRE SEQUENCING IN DRUG DISCOVERY AND DEVELOPMENT

Overall, 70.6% of respondents to a certain extent believe that insights from Rep-seq could potentially be valuable for their own business operations. Of the total number of respondents, 17.6% strongly agreed, 35.3% agreed, and 17.6% more or less agreed that these insights could potentially be valuable for their own business operations.

Possible applications of Rep-seq analysis that respondents could think of for their own organizations were “analysis of infiltrating T cells before, during and after treatment”, “screen treated patients before and after therapy”, “identify patients that have established tumor specific immune responses”, and “clone selection”.

Many more detailed findings, a list of references, a discussion of the results and conclusion by the author are now available in a 10-pages report.

Request your free copy of the survey report by submitting your contact details below.